Can MariMed’s $7.7M Illinois Cannabis Expansion Turn The Tide In A $496M Market?

In Zuanic & Associates‘ latest equity report, senior analyst Pablo Zuanic analyzes MariMed‘s (OTC:MRMD) performance across its core markets, with Illinois (IL) accounting for 40-45% of the company’s sales. 

Despite overall market stagnation, MariMed aims to boost growth through capacity expansion, including a new 14,000 sq ft cultivation site expected to begin sales by early 2025. 

Get Benzinga’s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can’t afford to miss out if you’re serious about the business.

Q3

In Q3, Illinois’ cannabis sales reached $496 million, with 86% from recreational use. However, per capita spending remains at $160, lower than in states like Arizona ($178) and Michigan ($320). Retail flower prices fell 10% year-over-year to $8.87 per gram, and per-store revenue dropped from $17 million to $8.8 million annually.

“The Illinois market remains attractive due to high wholesale prices, but growth challenges persist, particularly for retailers without cultivation operations,” Zuanic said. Despite these challenges, MariMed’s in-house brands, launched in …

Full story available on Benzinga.com